Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Releases

70 Press Releases
DateTitleCompany
23 Feb 18 Shire Recognizes Rare Disease Day 2018 with Global Initiatives Focused on Reducing the Time to Diagnosis Shire ,
Published by
PharmiWeb.com
23 Feb 18 FDA Accepts Shire's BLA and Grants Priority Review for Lanadelumab for the Prevention of Attacks in HAE Patients Shire plc,
Published by
GlobeNewswire
22 Feb 18 Shire Recognizes Rare Disease Day 2018 with Global Initiatives Focused on Reducing the Time to Diagnosis Shire plc,
Published by
GlobeNewswire
20 Feb 18 Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases Shire plc,
Published by
GlobeNewswire
13 Feb 18 Shire Provides Regulatory Progress Update for Key Pipeline Programs Targeting Rare Disease Shire plc,
Published by
GlobeNewswire
05 Feb 18 Shire to Highlight Advancements in Diagnosis, Treatment and Management of Rare Lysosomal Diseases at Global Conference Shire plc,
Published by
GlobeNewswire
01 Feb 18 Shire plc : Total voting rights Shire plc,
Published by
GlobeNewswire
01 Feb 18 Shire presentations at EAHAD 2018 demonstrate commitment to studying outcomes in patients with bleeding disorders Shire plc,
Published by
GlobeNewswire
30 Jan 18 AB Biosciences and Shire Enter Into Agreement for Development and Commercialization of AB Biosciences' PRIM Program Shire plc,
Published by
GlobeNewswire
24 Jan 18 FDA Grants Approval to Shire for Technology Transfer of CINRYZE® Drug Product Manufacturing Process to Vienna, Austria Manufacturing Site Shire plc,
Published by
GlobeNewswire
23 Jan 18 Shire Continues to Uphold High Standards of Ethics and Transparency with Adoption of Open Access Policy for Publication of Shire-Supported Research Shire plc,
Published by
GlobeNewswire
23 Jan 18 Shire Continues to Uphold High Standards of Ethics and Transparency with Adoption of Open Access Policy for Publication of Shire-Supported Research Shire ,
Published by
PharmiWeb.com
08 Jan 18 Shire Announces Business Update at 36th Annual J.P. Morgan Healthcare Conference Shire ,
Published by
PharmiWeb.com
08 Jan 18 Shire Announces Business Update at 36th Annual J.P. Morgan Healthcare Conference Shire plc,
Published by
GlobeNewswire
04 Jan 18 Shire plc : Shire Receives FDA Breakthrough Therapy Designation for Maribavir, an Investigational Treatment for Cytomegalovirus (CMV) Infection in Transplant Patients Shire plc,
Published by
GlobeNewswire
04 Jan 18 Shire to present at the 36th Annual J.P. Morgan Healthcare Conference Shire plc,
Published by
GlobeNewswire
03 Jan 18 Shire plc : Xiidra® Approved by Health Canada To Treat the Signs and Symptoms of Dry Eye Disease Shire plc,
Published by
GlobeNewswire
03 Jan 18 Xiidra®* (Lifitegrast Ophthalmic Solution 5%) Approved by Health Canada To Treat the Signs and Symptoms of Dry Eye Disease Shire Canada,
Published by
PR Newswire
19 Dec 17 SHIRE RECEIVES FDA CLEARANCE FOR MYPKFIT(TM) FOR ADVATE® [ANTIHEMOPHILIC FACTOR (RECOMBINANT)] TO HELP PERSONALIZE CARE FOR HEMOPHILIA A Shire plc,
Published by
GlobeNewswire
19 Dec 17 SHIRE RECEIVES FDA CLEARANCE FOR MYPKFIT™ FOR ADVATE® [ANTIHEMOPHILIC FACTOR (RECOMBINANT)] TO HELP PERSONALIZE CARE FOR HEMOPHILIA A SHIRE ,
Published by
PharmiWeb.com
19 Dec 17 SHIRE RECEIVES FDA CLEARANCE FOR MYPKFIT(TM) FOR ADVATE® [ANTIHEMOPHILIC FACTOR (RECOMBINANT)] TO HELP PERSONALIZE CARE FOR HEMOPHILIA A Shire plc,
Published by
GlobeNewswire
19 Dec 17 SHIRE RECEIVES FDA CLEARANCE FOR MYPKFIT(TM) FOR ADVATE® [ANTIHEMOPHILIC FACTOR (RECOMBINANT)] TO HELP PERSONALIZE CARE FOR HEMOPHILIA A Shire plc,
Published by
GlobeNewswire
20 Dec 17 SHIRE RECEIVES FDA CLEARANCE FOR MYPKFIT(TM) FOR ADVATE® [ANTIHEMOPHILIC FACTOR (RECOMBINANT)] TO HELP PERSONALIZE CARE FOR HEMOPHILIA A Shire plc,
Published by
GlobeNewswire
20 Dec 17 SHIRE RECEIVES FDA CLEARANCE FOR MYPKFIT(TM) FOR ADVATE® [ANTIHEMOPHILIC FACTOR (RECOMBINANT)] TO HELP PERSONALIZE CARE FOR HEMOPHILIA A Shire plc,
Published by
GlobeNewswire
20 Dec 17 SHIRE RECEIVES FDA CLEARANCE FOR MYPKFIT(TM) FOR ADVATE® [ANTIHEMOPHILIC FACTOR (RECOMBINANT)] TO HELP PERSONALIZE CARE FOR HEMOPHILIA A Shire plc,
Published by
GlobeNewswire
20 Dec 17 SHIRE RECEIVES FDA CLEARANCE FOR MYPKFIT(TM) FOR ADVATE® [ANTIHEMOPHILIC FACTOR (RECOMBINANT)] TO HELP PERSONALIZE CARE FOR HEMOPHILIA A Shire plc,
Published by
GlobeNewswire
20 Dec 17 SHIRE RECEIVES FDA CLEARANCE FOR MYPKFIT(TM) FOR ADVATE® [ANTIHEMOPHILIC FACTOR (RECOMBINANT)] TO HELP PERSONALIZE CARE FOR HEMOPHILIA A Shire plc,
Published by
GlobeNewswire
20 Dec 17 SHIRE RECEIVES FDA CLEARANCE FOR MYPKFIT(TM) FOR ADVATE® [ANTIHEMOPHILIC FACTOR (RECOMBINANT)] TO HELP PERSONALIZE CARE FOR HEMOPHILIA A Shire plc,
Published by
GlobeNewswire
20 Dec 17 SHIRE RECEIVES FDA CLEARANCE FOR MYPKFIT(TM) FOR ADVATE® [ANTIHEMOPHILIC FACTOR (RECOMBINANT)] TO HELP PERSONALIZE CARE FOR HEMOPHILIA A Shire plc,
Published by
GlobeNewswire
27 Dec 17 Shire files for FDA approval of a new plasma manufacturing facility in Covington, Georgia to support growing Immunology franchise Shire plc,
Published by
GlobeNewswire
Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.